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Abstract A high-resolution screening method was devel-
oped for the p38α mitogen-activated protein kinase to
detect and identify small-molecule binders. Its central role
in inflammatory diseases makes this enzyme a very
important drug target. The setup integrates separation by
high-performance liquid chromatography with two parallel
detection techniques. High-resolution mass spectrometry
gives structural information to identify small molecules
while an online enzyme binding detection method provides
data on p38α binding. The separation step allows the
individual assessment of compounds in a mixture and links
affinity and structure information via the retention time.
Enzyme binding detection was achieved with a competitive
binding assay based on fluorescence enhancement which
has a simple principle, is inexpensive, and is easy to
interpret. The concentrations of p38α and the fluorescence
tracer SK&F86002 were optimized as well as incubation
temperature, formic acid content of the LC eluents, and the
material of the incubation tubing. The latter notably
improved the screening of highly lipophilic compounds.
For optimization and validation purposes, the known kinase
inhibitors BIRB796, TAK715, and MAPKI1 were used
among others. The result is a high-quality assay with Z′
factors around 0.8, which is suitable for semi-quantitative
affinity measurements and applicable to various binding
modes. Furthermore, the integrated approach gives affinity
data on individual compounds instead of averaged ones for
mixtures.
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Introduction
Kinases are certainly among the most important target
classes in contemporary drug discovery [1]. The mitogen-
activated protein (MAP) kinase p38 (p38) is one prominent
example of a drug target kinase, especially its most
important isoform p38α [2, 3]. It is involved in signal
transduction pathways, transmitting signals through succes-
sive activation by phosphorylation [4]. Being one of the
important mediators for a cell’s response to extracellular
stimuli, this pathway presents a promising opportunity for
drug intervention [5]. Because p38α is heavily involved in
inflammation processes, the envisaged diseases are mostly
chronic inflammatory diseases like rheumatoid arthritis,
psoriasis, or Crohn’s disease [6]. Several p38α inhibitors,
which target these diseases, are currently in different stages
of preclinical and clinical development up to phase II [3, 7].
Nearly all known kinase inhibitors show interactions with
the highly conserved adenosine triphosphate (ATP)-binding
pocket. Therefore, most early kinase inhibitors, possessing
only these interactions, exhibited poor kinase selectivity
[5]. Although different systems of categorization exist,
these will be called type I inhibitors. Type I inhibitors used
in this study are TAK715 [8], MAP kinase inhibitor 1
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(MAPKI1) from Merck KGaA [9], and SK&F86002 (SKF)
[9]. The discovery of an allosteric binding pocket adjacent
to the ATP-binding site led to the discovery of inhibitors
using both sites (type II). BIRB796 is a prominent example
of this type of binding [10, 11]. Consequently, type III
binders like 1-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)-3-(4-
chlorophenyl)urea (pyrazolourea) are targeting only this
allosteric site [12]. The type IV inhibitors are not binding to
either of the two pockets, as has been discovered, e.g., for
GNF-2 binding to the Brc-abl kinase [13]. The importance
of p38α has led to a multitude of assay principles for the
identification of small molecules targeting this kinase [14,
15]. Among the cell-free in vitro formats for p38α, those
based on activity and those based on affinity can be
distinguished. As readout for activity-based methods,
scintillation [11] and fluorescence polarization [16] have
been used among others [14, 15]. These formats require
expensive reagents (antibodies, etc.) and rely on labels
which can impair the usefulness of results, or they involve
handling radioactivity. In addition to these drawbacks,
activity assays can, by definition, not employ the non-
phosphorylated kinase as target. This is the advantage of
affinity-based assays. However, scintillation [17], chemilu-
minescence [16], and fluorescence polarization [18] suffer
from similar reagent-based drawbacks as mentioned above.
Furthermore, some label-free technologies, like surface
plasmon resonance [16] or isothermal titration calorimetry
[19], have been employed, which avoid additional reagents
and the problems of molecular probes. Still, these techni-
ques are complex, and instrumental requirements and
logistics may limit their throughput. A relatively simple
approach was used by Pargellis et al. during the discovery
of BIRB796 [10, 11]. The method is based on fluorescence
enhancement and requires solely native p38 and the small
molecule kinase inhibitor SKF. SKF shows fluorescence,
which is strongly enhanced upon binding to the target
enzyme. Therefore, high fluorescence intensity indicates a
high concentration of the enzyme–tracer complex. A com-
pound showing affinity to the target enzyme will compete
with the tracer, thus reducing the concentration of enzyme–
tracer complex and thereby reducing the fluorescence. This
principle enables a competitive binding assay in a homoge-
neous setup, which is based on the strong difference in
fluorescence intensity between the free tracer and the
enzyme–tracer complex. Because of its convenience and the
possibility to use non-phosphorylated p38α as target, this
technique presented a good basis for the development of a
high-resolution screening (HRS) platform. HRS is defined by
the combination of separation and screening in an integrated
system. Therefore, it enables the affinity assessment and the
simultaneous structural characterization of individual com-
pounds in mixtures [20, 21]. This feature makes HRS
platforms especially attractive when complex mixtures such
as metabolic incubations [22], combinatorial mixtures [21],
or natural extracts [23] are screened where dereplication,
affinity, and structural information are crucial. In contrast to
conventional high-throughput screening (HTS), isolation of
individual compounds not showing affinity can be avoided.
Thus, the laborious development of high-yield synthesis and
isolation methods can be limited to compounds showing the
desired affinity. One common approach in HRS is the use of
online post-column assays, which have been recently
reviewed by Shi et al. [24]. Colorimetry-, fluorescence-, and
mass-spectrometry-based readouts were developed in both
homogeneous and inhomogeneous formats. Homogeneous
setups are easier to apply, so their significance exceeds
inhomogeneous setups in cases where background fluores-
cence is of minor importance. However, HRS formats
described so far are either activity-based [21, 23] or target
a receptor [20, 22]. We report the implementation of the
enzyme p38α as the first kinase to be targeted in an online
post-column binding assay (HRS system). Furthermore, the
screening of highly lipophilic molecules was greatly im-
proved by the unprecedented use of covalently modified
fused silica tubing as material for post-column incubation,
resulting in improved affinity signals.
Materials and methods
Materials
Human recombinant p38α, ORGX, BIRB796, and TAK715
were a kind gift of MSD Research Laboratories (Oss, the
Netherlands). SKF andMAPKI1 were purchased fromMerck
KGaA (Darmstadt, Germany). Enzyme-linked immunosor-
bent assay (ELISA) blocking reagent was delivered by Roche
Diagnostics (Mannheim, Germany). Pyrazolourea was
obtained from Ambinter (Paris, France). All other chemicals
were from Sigma-Aldrich (Schnelldorf, Germany). Fused
silica tubing (250-μm inner and 375-μm outer diameter)
untreated or covalently coated with polyethylene glycol
(PEG), methyl, or methyl/phenyl groups was also purchased
from Sigma-Aldrich (Schnelldorf, Germany). Black polypro-
pylene microtiter plates with ninety-six “flat”-bottom chim-
ney wells from Greiner Bio-one (Alphen a/d Rijn, The
Netherlands) were used. Methanol (liquid chromatography
(LC)–mass spectrometry (MS) grade) and formic acid (ULC–
MS grade) were obtained from Biosolve (Valkenswaard, the
Netherlands). Purified water was generated with a Milli-Q
academic from Millipore (Amsterdam, the Netherlands).
Instrumentation
Ninety-six-well plate experiments were performed on a
Victor3 plate reader from Perkin-Elmer (Groningen, the
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Netherlands). The setup used for the online assay
included two LC-20 AD and two LC-10 AD isocratic
pumps, a SIL-20 AC autosampler, one CTO-20 AC and
one CTO-10 AC column oven, an RF-10AXL fluores-
cence detector, a CBM-20A controller, and an ion trap
time-of-flight (IT-TOF) mass spectrometer equipped with
an ESI source, all products of Shimadzu (’s Hertogenbosch,
the Netherlands). HR-MS spectra were obtained from m/z
200 to 650, switching positive- and negative-ion mode
with 10-ms accumulation time each. The curved desolva-
tion line and the heating block were equilibrated at 200 °C
and the voltages applied were 5 kV to the interface and
1.7 kV to the detector. Nitrogen (99.9990%) was used at
flows of 1.5 and 10 L/min as nebulizing gas and drying
gas, respectively. To allow accurate mass measurements,
external calibration of the IT-TOF was performed using
TFA clusters.
Furthermore, two superloops and two pulse dampeners
made in-house were used.
Plate reader assay
A 20 mM Tris–HCl buffer (pH 7.5), containing 10 mM
MgCl2, 2 g/L PEG 6000, and 0.2 g/L ELISA blocking
reagent (Tris buffer), was used in all experiments. All
solutions of p38α were prepared in Tris buffer. Enzyme
stock solutions were stored at −80 °C until use. During
online experiments, the enzyme solutions were kept at 0 °C.
A stock solution of SKF (2 mM) was made in dimethyl
sulfoxide (DMSO) and further diluted with Tris buffer.
Solutions of inhibitors were prepared in 1:1 water/methanol
containing 0.01% formic acid from 2- to 5-mM stock
solutions in methanol (DMSO in case of MAPKI1). Small-
molecule stock solutions were stored at −20 °C.
For plate reader measurements, the wells were filled with
50 μL enzyme solution, 12.5 μL inhibitor solution, and
50 μL SKF solution in the given order. Fluorescence was
measured at 25 °C with the wavelength of absorption and
emission being 355±4 and 405±5 nm, respectively. The
sum of ten flashes was used as readout to improve
performance. Saturation of a 90-nM solution of p38α with
SKF was determined by using a concentration range from
40 to 2,500 nM of SKF. The Z′ factor is a measure for assay
quality. If not otherwise stated, it was calculated according
to the original publication of Zhang et al. [25]. A more
detailed explanation is given in the “Results and discussion”
section. Measurements of the Z′ factor dependence on
enzyme concentration were performed on 3 days with five
repeats per day and a final concentration of 3 μM SKF. For
full inhibition, TAK715 was added to a final concentration
of 1 μM, while the control values contained only the
corresponding amount (see above) of high-performance
liquid chromatography (HPLC) solvents.
Online assay
HPLC solvents were 100:1 water/methanol (solvent A) and
100:1 methanol/water (solvent B), both containing 0.01%
formic acid. The instrumental setup described by de Vlieger
et al. [20] was used for the analysis, with one enzyme
binding detection line and the following modifications (cf
Fig. 1). HPLC was done either in flow injection analysis
(FIA) mode (where no separation column is present) or
with a SunFire C18 column 30×2.1 mm, 3.5-μm particles
(Waters, Milford, MA, USA; Fig. 1, 2). Ten microliters of
the sample was injected (Fig. 1, 1) into a flow of 113 μL/
min. Elution was performed at 40 °C, either isocratic at
different methanol concentrations or using a binary gradi-
ent. Post-column, the flow was split 1:9 (Fig. 1, 3), sending
100 μL/min to high-resolution mass spectrometry (HR-MS)
detection and 13 μL/min to the enzyme binding detection.
To the 13 μL/min HPLC eluent, first 50 μL/min of a
200 nM p38α solution was added (Fig. 1, 4) and thereafter
50 μL/min of a 1,400-nM solution of SKF (Fig. 1, 6).
Fig. 1 Scheme of the online setup. The system enables the separation
of mixtures and subsequent parallel detection of enzyme binding and
accurate mass. The samples are injected (1) into and separated (2) by
an HPLC system. The eluent is split (3) between HR-MS and enzyme
binding detection. The fraction which enters the enzyme binding
detection is mixed with the target (4) and the tracer (6) and incubated
after each mixing step, 24 s for the target–ligand interaction (5) and
11 s for the target–tracer interaction (7). Finally, the fluorescence is
measured (8) as readout of affinity towards p38α. In parallel, the
second part of the eluent is analyzed by HR-MS (9), delivering
structural information to identify the small molecules tested
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These solutions were constantly released by a linear setup
of an LC-10 AD pump, a pulse dampener with restriction
capillary, and a superloop each. Following each addition,
the mixture was incubated in PEG-deactivated fused silica
loops of 25 μL (Fig. 1, 5) and 20 μL (Fig. 1, 7),
respectively. The incubation loops were kept at 25 °C in a
second column oven. The resulting incubation times were
24 s for the target–ligand interaction (Fig. 1, 5) and 11 s for
the target–tracer interaction (Fig. 1, 7). Finally, at concen-
trations of 90 nM p38α and 630 nM of SKF, the
fluorescence was measured with excitation at 355±7.5 nm
and emission at 425±7.5 nm (Fig. 1, 8). The used detector
settings were gain 4, recorder range 1, and sensitivity
medium.
The influence of the methanol concentration on the
maximum signal was assessed in two consecutive measure-
ments. To this end, a stepwise gradient was used starting at
100% A and increasing the fraction of B by 15% approxi-
mately every 10 min. In the first run, the baseline without
inhibition was recorded. In the second run, MAPKI1 was
added to the SKF solution for full inhibition, reaching a final
assay concentration of around 0.9 μM. By comparing these
measurements, the assay window in relation to the different
organic modifier concentrations can be estimated.
In order to assess the influence of the incubation tubing
material, two measurements were carried out, in which the
volume and therefore the incubation time were kept
constant: in the first experiment, polyether ether ketone
(PEEK) of 250-μm and 170-μm inner diameter (ID),
polytetrafluoroethylene (PTFE) of 250-μm ID, and untreat-
ed fused silica of 250-μm ID were compared by injecting a
2-μM solution of ORGX in FIA mode at 60% B. In a
second experiment, 250-μm ID fused silica tubings with
covalent coatings of different polarity were compared. In
these experiments, a 20-μM solution of ORGX was
injected in FIA mode at 60% B. The coatings were PEG
(polar), a mixture of phenyl and methyl groups (interme-
diate), or methyl groups only (non-polar).
The online Z′ factor was calculated from triplicate
injections each of a control (blank) experiment and a full
inhibition sample on five different days. The full inhibition
sample was a mixture of 50 μM BIRB796, 20 μM ORGX,
and 20 μM TAK715 while the control sample was a 1:1
mixture of the solvents. The separation was carried out with
the following gradient: 0 to 1.0 min isocratic at 50% B, 1.0
to 12.5 min linear to 90% B, 12.5 to 14.5 min isocratic at
90% B, 14.5 to 15.0 min linear to 50% B, and 15.0 to
21.0 min isocratic at 50% B.
MAPKI1 and TAK715were tested in amixture with six drug
molecules to simulate a screening situation. Carbamazepine,
norethisterone, warfarin, phenylbutazone, celecoxib, and
diclofenac were used as test compounds without p38α
affinity. TAK715 was injected at 20-μM concentration,
the others at 50 μM. The mixture was separated with the
following gradient: 0 to 2.0 min isocratic at 50% B, 2.0
to 32.0 min linear to 70% B, 32.0 to 38.0 min isocratic
at 70% B, 38.0 to 38.5 min linear to 50% B, and 38.5 to
50.0 min isocratic at 50% B.
For the measurements of IC50 values, isocratic elution
was applied, taking care that the substance peak showed
separation from the injection peak. TAK715 was eluted at
85% B, BIRB796 at 50%, and MAPKI1 at 70%. Solutions
of nine different concentrations for each inhibitor were
prepared in 50% methanol, 50% water, and 0.01% formic
acid from 5-mM stock solutions of TAK715 and BIRB796
in methanol or a 2-mM stock solution of MAPKI1 in
DMSO. The following concentrations for each inhibitor
were prepared: 50, 100, 200, 500 nM, 1, 2, 5, 10, and
20 μM for TAK715; 500 nM, 1, 2, 5, 10, 20, 50, 100, and
200 μM for BIRB796; and 200, 500 nM, 1, 2, 5, 10, 20, 50,
and 100 μM for MAPKI1. These nine concentrations and a
blank were injected in triplicate for every inhibitor.
To finalize the binding mode studies, the pyrazolourea
compound was used as an example of a type III inhibitor. It
was injected at a concentration of 100 μM and tested under
isocratic conditions at 70% B.
Results and discussion
Assay condition optimization
Optimization was carried out in a 96-well format. The
protocol of Regan et al. [10] was used with some
modifications. Since Mg2+ ions are known to be involved
in ATP binding and can potentially influence binding of
inhibitors to the ATP-binding site, MgCl2 was added.
Furthermore, ELISA blocking reagent and PEG 6000 were
added in order to avoid non-specific binding and unwanted
interactions with the material of the enzyme binding
detection [26]. Enzyme and tracer concentrations were
optimized under these conditions. The fluorescence signal
showed a linear dependence on the enzyme concentration
(cf Online Resource 1 Fig. S1). The most suitable p38α
concentration was therefore chosen by considering the Z′
factor measurements. The signal dependence on the tracer
concentration, depicted in Fig. 2a, displays the asymptotic
form of saturation behavior. The final concentration of
630 nM SKF is selected to be slightly above the saturation
value. This choice presents a compromise between avoiding
deviations of the signal due to variability in the tracer
concentration and maximizing the sensitivity with regard to
detection limits for binders. Namely, competition reduces
this sensitivity with increasing tracer concentration.
There are several factors mainly related to the HPLC
separation system, which can have a negative influence on
1774 D. Falck et al.
the assay performance. Methanol, formic acid, and the
incubation temperature are the most prominent of these
variables. Using typical HPLC conditions such as 50%
methanol and 0.1% formic acid at 37 °C completely
inhibited the fluorescence enhancement. As a result, these
factors were carefully optimized and need to be controlled
cautiously. The influence of organic modifier at no and full
inhibition is shown in Fig. 2b. The assay window decreased
with increasing organic modifier (methanol) content.
However, the Z
0
chrom factors for the different compounds
measured at different MeOH concentrations, due to gradient
elution, showed only minor differences, thereby proving the
robustness of the online setup even at high methanol
concentrations. Increasing temperature also yielded a
similar decrease in maximum signal as seen with methanol.
In order to guarantee robustness and enable the use of up to
90% methanol in the HPLC separation, the formic acid
concentration in the eluent and the incubation temperature
were restricted to 0.01% and 25 °C, respectively. Hence,
the temperatures of the HPLC separation step and the
enzyme binding detection were controlled separately.
The screening of highly lipophilic compounds is not
only challenging in off-line screening due to adhesion and
solubility issues [27] but also presents challenges in online
screening approaches [26]. In online screening systems, the
amount of organic modifier is usually kept low to prevent
protein degradation. On the other hand, the tubing used for
incubation loops is mostly PEEK or PTFE. The favored
interaction of non-polar compounds with these surfaces
results in peak broadening and tailing, thus decreasing
resolution and sensitivity. By using polar material for the
incubation loops, this effect was significantly decreased.
Figure 3a shows a twofold to threefold increase in signal
height and reduced tailing when untreated fused silica
tubing is used instead of PEEK. Although PTFE compared
to PEEK already yields decreased peak width, the width is
additionally approximately halved with untreated fused
silica. The polarity of the incubation coil material plays a
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Fig. 2 Optimization of the p38α affinity assay. a Saturation curve of
the tracer for 90 nM p38α (n=3). Full saturation was reached at
630 nM SKF, which was consequently the selected tracer concentra-
tion. b Influence of the organic modifier concentration on the enzyme
binding detection. I is the baseline at different percentages of organic
modifier in HPLC mobile phase, which shows the maximum signal
reached at these different MeOH concentrations. In opposition, line II
shows the fluorescence signal at maximum inhibition; hence, the
difference between both lines describes the maximum assay window.
II was measured by premixing SKF with MAPKI1 (900 nM final
concentration) in the superloop
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Fig. 3 Influence of the reaction coil material on the peak shape. a
PEEK and PTFE were compared with untreated fused silica tubing. A
2-μM solution of ORGX was injected in FIA mode at 60% methanol.
b At the same conditions, a 20-μM solution of the same inhibitor was
injected. Fused silica tubing with covalent coatings of either PEG
(polar), a mixture of methyl and phenyl groups (intermediate), or only
methyl groups (non-polar) was compared for their influence. In both
experiments, peak width and asymmetry increased with decreasing
polarity while the peak height decreased as a consequence. Fused
silica tubing, coated with PEG (polar), exhibited drastically improved
performance over the compared materials
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crucial role in explaining these findings. This can clearly be
seen in Fig. 3b where the influence of fused silica tubing
with covalent coatings of different polarities on the peak
shape was compared. The polar (PEG-coated) tubing gave
the best results while peak height and shape degraded
towards intermediate (methyl/phenyl-coated) and non-polar
(methyl-coated) surfaces. This indicates the influence of
tubing polarity on post-column band broadening and
justifies a preference of polar-coated fused silica tubing
over PEEK and PTFE in the presented study, taking the
structural features of the studied compounds into account.
Validation of the p38α binding assay
The quality of the p38α binding assay was assessed using
the method of Zhang et al. [25]. The Z′ factor is introduced
as a single value to judge assay quality because it
incorporates the SD of signal and background as well as
the assay window. Therefore, it indicates the ability to
distinguish between signals and false positives or false
negatives. According to this method, the Z′ factor was
calculated with Eq. 1 for several enzyme concentrations in
the plate-reader-based setup. μs and μc are defined as the
average signal of the sample and the control, respectively.
Consequently, σs and σc are the standard deviations (SD) of
these values.
Z 0 ¼ 1 3ss þ 3scð Þ
ms  mcj j
ð1Þ
For the sake of comparability, the number of experi-
ments (n=15) was kept the same in plate-reader- and
online-based measurements. However, this is recognized as
a relatively low number for plate reader experiments.
Therefore, an additional plate reader experiment with n=
50 was performed, yielding a Z′ factor of −0.02. The
conclusion from both experiments was as follows: the
plate-reader-based assay at 90 nM p38α gave insufficient
results with Z′ factors lower than zero. In the plate reader
assay, a Z′ factor above 0.5, indicating an excellent assay,
could only be achieved by raising the p38α concentration
to 450 nM. Table 1 compares these data with the results of
the online setup, in which 90 nM p38α was sufficient for an
excellent assay. As a confirmation, the signal-to-noise ratios
(S/N) were also calculated (Table 1), resulting in the same
conclusions.
Regardless of the findings of the last paragraph, the
online setup has two disadvantages. Reagent consumption
is usually higher in an online setup than in a plate-reader-
based assay. Furthermore, the separation step introduces an
additional dilution due to chromatographic peak broaden-
ing, which requires higher analyte concentrations. There are
additional differences between the two setups, which
should be adequately reflected in the Z′ factor. Kool et al.
already applied the Z′ factor to chromatography-based
online assays, adapting the variables of Eq. 1 in order to
take into account these discrepancies [28]. A main
advantage is the internal control value (μc) represented by
the baseline, which is more relevant than an external
control, because it is available for each individual experi-
ment. For a complete consideration of the differences
between the online and the plate reader setup, all classical
variables are systematically substituted with parameters
more suitable to the online approach. Doing this without
compromising the comparability of this Z′ factor is not
trivial but possible. The assay window (μc−μs), as
determined by the difference of the mean of control (no
inhibition) and signal (full inhibition), could more suitably
be expressed as the mean of the peak height of full
inhibition (μH), thereby still describing the desired param-
eter. Thus, the assay window is automatically corrected for
changes in the baseline, representing the internal control.
The SD of the sample (σs) would then consequentially be
identified with the SD of the peak heights at full inhibition.
For the control, usually, no signals are obtained, and
changes of the baseline between samples are irrelevant as
they have already been taken into account. The SD of the
control (σc) can therefore logically be identified with the
baseline deviation within one sample. This value is, in
chromatography, better known as the noise. The measure of
three times the noise is often used as limit of detection. This
is consistent with the ideas behind the Z′ factor as both
interpretations of 3σc are aimed at avoiding false positives.
In summary, the transition from an external control to an
internal one strengthens the reproducibility and accuracy of
Table 1 Z′ factors and S/N for plate-reader- and/or online-based
enzyme binding detection
Inhibitora c (p38α) (nM) Z′ or Z
0
chrom
b (n=15) S/N
Plate reader TAK715 90 −0.41 4
180 0.49 12
270 0.36 23
360 0.49 55
450 0.75 48
Online BIRB796 90 0.77 70
ORGX 90 0.82 106
TAK715 90 0.80 97
a Concentration of the inhibitor was 1 μM TAK715 (final concentration) in
the plate reader experiments. In the online setup, ORGX and TAK715 were
injected at 20-μM concentration and BIRB796 at 50 μM concentration for
this purpose
b In the plate reader experiments, the Z′ factor was calculated according to
Eq. 1. For the online experiments, Eq. 2 was used, yielding the Z
0
chrom
factor
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the assay and should therefore be appropriately reflected in
the determination of Z′ factors. Therefore, an adjusted Z′
factor for the use in online systems is proposed in Eq. 2 on
the basis of the previous argumentation.
Z
0
chrom ¼ 1
3SDH þ 3  noiseð Þ
mHj j
ð2Þ
The new interpretation of the Z′ factor could also be used
to omit the measurements of a control, significantly
shortening the time of Z
0
chrom factor determination. Because
the noise is calculated from the baseline of the chromato-
gram, a prerequisite is to have an empty time frame to
observe both required values. Therefore, the first 4 min of
the enzyme binding detection chromatogram was used to
determine the noise. The mean noises calculated from
signal and control runs were identical, thus proving the
redundancy of the control measurements for Z
0
chrom factor
determinations.
The repeatability of triplicates is excellent, which is
clearly visible in Figs. 4, 5, and 6. This is true for the
enzyme binding detection responses as well as for the
chromatographic parameters like peak width, measured as
full width at half maximum (FWHM), and retention time
(tr). For the enzyme binding detection, the relative SDs are
≤10% for FWHM and <3% for tr. Low variability and noise
compared to the total signal result in the high Z′ factor and
S/N shown in Table 1. The high Z′ factors indicate the
excellent intraday and interday reproducibility, However,
the online setup showed comparable Z′ factors at five times
lower enzyme concentration than needed in the plate-based
assay. This is directly related to the minimal measurable
IC50. While IC50 values down to 45 nM can be distin-
guished in the online method, the plate reader method only
allows differentiation of IC50 values of 230 nM and higher.
Furthermore, the higher enzyme concentration needed
diminishes the advantage of the plate setup with regard to
reagent consumption. Therefore, the online setup has
advantages beside the additional possibilities associated
with separation.
High-resolution screening of mixtures
In order to assess whether the presented HRS method was
suitable for the identification of small-molecule binders of
p38α in mixtures, a solution of eight compounds was
screened. Two of these were the kinase inhibitors MAPKI1
and TAK715 while the other six were drug molecules from
different classes. As illustrated in Fig. 5, all eight
compounds could be separated for individual identification
and affinity assessment. Based on HR-MS data, the
structure was linked to a retention time. Accurate mass
measurements enabled the unambiguous distinction of all
compounds as two of them differed by less than 0.05 U. In
case of more scarce knowledge of the sample, structure
elucidation can be facilitated by HR-MSn experiments [21].
In parallel to the structure confirmation, the retention time
Fig. 4 Comparison of MS and enzyme binding detection chromato-
gram. The matching of the fluorescence trace of the enzyme binding
detection (above) and the total ion current (TIC) of the MS (below) for
BIRB796 (1), ORGX (2), and TAK715 (3) are shown. Depicted is a
triplicate from the Z
0
chrom factor determination. The excellent repro-
ducibility in response, peak shape, and retention time are clearly
visible for both the enzyme binding detection and the MS signal. The
low variability enables an easy and accurate matching of the two
traces
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Fig. 5 HRS of a mixture of kinase inhibitors and drug molecules.
MAPKI1 (4) and TAK715 (8) were mixed with carbamazepine (1),
norethisterone (2), warfarin (3), phenylbutazone (5), celecoxib (6), and
diclofenac (7). The mixture was separated by HPLC and measured
with HR-MS and enzyme binding detection in parallel. Accurate mass
measurements with low deviation (<8 ppm) and well-matched isotope
patterns allowed unambiguous identification. Structure and affinity
were easily matched via the corrected retention times. Consequently,
the two affinity compounds were detected in the mixture
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is also linked with affinity information through the enzyme
binding detection. However, the readout of the enzyme
binding detection is delayed compared to the HR-MS
readout because of a higher void volume and a lower
average flow rate after splitting. This delay was measured
to be 0.5 min by comparing both detection times in several
experiments. It remains constant as long as void volume
and flow rates are unchanged. The retention time corrected
for this delay is used to couple affinity to identity
information. Two affinity peaks were detected, which were
linked to the elution of the kinase inhibitors. In conclusion,
the approach presents a fast method to match the structure
and activity of compounds in mixtures.
Semi-quantitative affinity measurements
Several known p38α inhibitors were tested for their dose-
related responses in the enzyme binding detection. There-
fore, their injected concentrations had to be converted to
final assay concentrations by taking into account the
dilution factors. On one hand, splitting of the HPLC eluent
and subsequent mixing with the reagents led to dilution.
This can be easily calculated from the ratios of the flow in
the beginning and the end of the enzyme binding detection
(113/13=9). On the other hand, the chromatographic
dilution, meaning the transition from an injected plug to a
series of peaks of (assumed) Gaussian shape, has to be taken
into account. The corresponding calculations have been
described elsewhere [29]. The necessary peak parameters
were taken from the enzyme binding detection. By dividing
the injected concentration by the product of both dilution
factors, the final concentration at maximum peak height can
be calculated and used in the IC50 calculations (for a brief
description, see Online Resource 1).
Dose–response curves depicted in Fig. 6 were measured
in triplicate with excellent R2 values of >0.998 and minimal
SD of the triplicates (<2% SD relative to assay window).
This shows again the excellent reproducibility and accuracy
of the assay. The IC50 values and, given in brackets, their
95% confidence intervals, calculated after correcting the
concentrations for the dilution factors, are 81 nM (71 to
92 nM) for TAK715, 400 nM (360 to 440 nM) for
BIRB796, and 760 nM (530 to 1,100 nM) for MAPKI1.
If the inhibitors are ranked for their affinity, the obtained
results are in agreement with other methods, stating values
of 7.1 nM for TAK715 [8], 18 nM for BIRB796 [10], and
35 nM for MAPKI1 [9]. However, the absolute values of
measurements are ten to 20 times higher than in literature.
This can be explained by the profound differences in the
assay formats. While the reported method gives affinities,
the reference values were obtained by either activity assays
(TAK715) or cell-based functional assays (BIRB796,
MAPKI1). Another specific reason responsible for this
deviation is the slow binding kinetics of BIRB796. This
compound is known to show an up to 12-fold deviation of
its IC50 value, depending on the incubation time [11].
Despite the aforementioned issues, the method was proven
to be suitable for the semi-quantitative assessment of small-
molecule relative affinities towards p38α, serving as a
selection tool in the drug discovery process.
Applicability and binding modes
The type of binding to p38α as discussed in the
“Introduction” can have a significant influence on the
ability of a screening technology to detect this binding.
SKF is a type I binder and should therefore enable the
detection of type I and type II binders as they compete
for the ATP-binding pocket. This has been proven by the
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Fig. 7 Detection of the binding of the pyrazolourea type III inhibitor
to p38α. Triplicate injections of the inhibitor (black) showed signals in
the enzyme binding detection (top). In contrast, the control (gray) did
not show binding to p38α. HR-MS (bottom) confirmed the pyrazo-
lourea compound as the binder. This clearly shows the ability of the
assay to detect type III inhibitors. In combination with Fig. 4, it proves
the applicability to several types of p38α inhibitors (types I, II, and III)
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Fig. 6 Semi-quantitative data of the tested p38α inhibitors. Binding
curves are depicted for several known p38α inhibitors. The inhibitors
TAK715 (circles), BIRB796 (squares), and MAPKI1 (triangles) are
shown. Standard deviations of triplicate measurements were smaller
than data point size
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detection of TAK715 and MAPKI1 (type I) as well as
BIRB796 (type II). Furthermore, structural changes in
p38α upon binding of type III inhibitors may allow the
detection of such compounds. The rearrangement of
p38α from the DFG-in to the DFG-out conformation
results in a reorientation of Phe405, thereby affecting the
ATP-binding pocket. Hence, we tested the pyrazolourea
structure, which was discussed by Simard et al. as an
example of a type III inhibitor [12]. Figure 7 shows the
enzyme binding detection of this compound to p38α,
thereby proving the suitability of the method for the
detection of type III inhibitors. Consequently, the assay is
capable of detecting a wide range of p38α binders
including type I, II, and III binders.
Conclusion
An online binding assay for the separation and parallel
assessment of identity and affinity of small molecules in
complex mixtures towards non-phosphorylated p38α was
developed. In terms of applicability, the scope of the
presented HRS platform is different from conventional
HTS assays. HTS is more suited for the screening of
huge libraries where speed and low sample consumption
are essential. The value of HRS lies in the parallel
determination of structural and biochemical data of
potential binders. While an HTS assay will only give a
sum of compound affinities, HRS gives individual
information on all (separated) molecules. The aim was
to make available the advantages of the online approach,
mainly the measurement of mixtures and a comparison of
structure and affinity, for the important drug target p38α.
An online post-column enzyme binding detection based
on fluorescence enhancement was developed, and its
compatibility with modern HPLC separation techniques,
such as gradient elution and increased temperature, was
demonstrated. HR-MS as parallel readout is an integral
part of the developed screening platform, allowing the
identification of the tested molecules. Additionally, the
prospects of measuring compounds individually in
mixtures were demonstrated by matching identity and
affinity. Regarding the presented assay validation data, it
can be stated that a high-quality assay was achieved.
Finally, the assay provided ranking of various p38α
inhibitors (types I, II, and III), allowing the use within a
drug discovery process.
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